Recent News

• 04.15.2025 - 2024 Was a Good Year for CAR T-cell Therapies… 2025 Promises to Be Better
• 03.26.2025 - A Testament to The Science 18 Years in Remission After CAR T-Cell Therapy
• 03.13.2025 - CAR T-Cell Therapy is Very Expensive… But There Are Ways to Reduce Costs
• 02.27.2025 - The Market for Regenerative Medicine to Hit $235.98 Billion by 2032
• 02.12.2025 - Trump’s Massive Investment in AI Cancer Vaccines
• 02.06.2025 - CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
• 01.29.2025 - Breakthroughs Hope to Make CAR T-cell Cancer Therapies More Affordable
• 01.15.2025 - Malaysia and Singapore, Home to CytoMed Therapeutics, Launch Special Economic Zone to Attract Global Investment
• 12.17.2024 - Breakthroughs in CAR T-Cell Therapies Target Solid Cancer Tumors
• 12.04.2024 - The Massive Global Market For CAR-T Cell Therapies

Recent Filings

• 03.24.2025 - 144 Report of proposed sale of securities
• 03.24.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.14.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 03.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.06.2025 - EX-99.1 EX-99.1
• 12.05.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.20.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]